RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q4 2025
Top Holdings91 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
MADRIGAL PHARMACEUTICALS INC | 2M | $1.2B | 11.6% | $265.36 | +119.97% | 11 qtrssince 2023-Q2 | Unchanged 0 |
INSMED INC | 4.8M | $842.9M | 8.4% | $92.19 | +88.83% | 11 qtrssince 2023-Q2 | Increased 88 |
PTC THERAPEUTICS INC | 7.7M | $588.4M | 5.9% | $43.73 | +74.22% | 28 qtrssince 2019-Q1 | Unchanged 0 |
ARGENX SE - ADR | 673,497 | $566.4M | 5.7% | $355.08 | +135.97% | 28 qtrssince 2019-Q1 | Unchanged 0 |
PROTAGONIST THERAPEUTICS INC | 5.1M | $441.9M | 4.4% | $24.36 | +258.28% | 26 qtrssince 2019-Q3 | Decreased 0 |
NATERA INC | 1.5M | $343.6M | 3.4% | $42.13 | +445.90% | 26 qtrssince 2019-Q3 | Decreased 0 |
RadNet, Inc. | 3.9M | $281M | 2.8% | $55.94 | +27.79% | 9 qtrssince 2023-Q4 | Increased 70 |
TARSUS PHARMACEUTICALS INC | 3.3M | $273.1M | 2.7% | $36.05 | +128.40% | 21 qtrssince 2020-Q4 | Increased 56 |
Cogent Biosciences, Inc. | 7.6M | $269.7M | 2.7% | $26.62 | +39.44% | 2 qtrssince 2025-Q3 | Increased 85 |
PENUMBRA INC | 866,499 | $269.4M | 2.7% | $249.62 | +31.01% | 18 qtrssince 2021-Q3 | Unchanged 0 |
IRHYTHM TECHNOLOGIES INC | 1.2M | $209.7M | 2.1% | $178.57 | 0.00% | 1 qtr | New 79 |
APOGEE THERAPEUTICS INC | 2.7M | $204.7M | 2.1% | $28.34 | +167.35% | 10 qtrssince 2023-Q3 | Unchanged 0 |
APELLIS PHARMACEUTICALS INC | 7.7M | $192.6M | 1.9% | $25.24 | 0.00% | 1 qtr | New 70 |
ACADIA Pharmaceuticals Inc. | 7.1M | $190.8M | 1.9% | $18.54 | +44.02% | 15 qtrssince 2022-Q2 | Unchanged 0 |
ESTABLISHMENT LABS HLDGS INC | 2.6M | $188.7M | 1.9% | $26.83 | +171.76% | 28 qtrssince 2019-Q1 | Unchanged 0 |
STOKE THERAPEUTICS INC | 5.5M | $176.1M | 1.8% | $23.71 | +34.21% | 27 qtrssince 2019-Q2 | Increased 52 |
REPLIGEN CORP | 1.1M | $174.3M | 1.7% | $166.59 | 0.00% | 1 qtr | New 70 |
CYTOKINETICS INC | 2.7M | $172.9M | 1.7% | $28.96 | +119.40% | 22 qtrssince 2020-Q3 | Unchanged 0 |
IMMUNOCORE HLDGS PLC | 4.9M | $169M | 1.7% | $43.05 | -20.79% | 20 qtrssince 2021-Q1 | Unchanged 0 |
AXSOME THERAPEUTICS INC | 888,001 | $162.2M | 1.6% | $62.01 | +248.75% | 28 qtrssince 2019-Q1 | Decreased 0 |
RTW INVESTMENTS, LP manages $10B across 91 positions as of Q4 2025. Top holdings: MDGL (11.6%), INSM (8.4%), PTCT (5.9%). Fund DNA: Diversified Scout. HoldingsIntel Rating: 3/5.0.
Active quarter - 29 new positions, 12 exits, 20 increased. Top move: INSM (INCREASED, conviction 88). Portfolio: $10.0B across 91 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer